Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0364 for Smoking Cessation
NCT00109135Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2005
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Taranabant with Placebo (2 arms). Primary endpoint: Quitting smoking after 8 weeks of treatment. Started Jan 2005; status: completed.
02
Drugs
taranabant
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00109135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109135.